Arteriovenous Malformation (AVM) Causes
Arteriovenous Malformation (AVM) Causes
The first question most patients ask is what they did to cause it, and the answer is almost always nothing. A brain arteriovenous malformation arises during the formation of the cerebral vessels, before birth, when the capillary network that should sit between artery and vein fails to develop in one region. It is a developmental abnormality rather than a disease acquired in adult life, and for the great majority of patients there is no family history and no inherited condition behind it. There is one exception that genuinely changes the advice, and it is recognisable enough that patients can be told what to look for.
A developmental error, not a disease acquired later
The vascular system is assembled in stages. A primitive network of vessels is laid down and then remodelled, and the capillary bed is the part of that network through which blood is slowed before it reaches the veins. In an arteriovenous malformation, that stage does not complete normally in one region: the artery and the vein remain connected directly, and the intervening capillary bed does not form.
Because of this, the lesion is described as congenital in origin, which means present from birth rather than inherited. The distinction is worth insisting on. A parent who has spent months reviewing their pregnancy for a cause can be told plainly that the malformation formed during the assembly of the vessels, that the process is not under voluntary control, and that no action of theirs is a known cause.
The malformation is not static, though. It grows and remodels with the child, the vessels dilate under the flow they carry, and it can enlarge over years — which is why a lesion that was silent in childhood can present in adult life without having been "caused" at that point.
Why the shunt changes the vessels around it
Once the direct connection exists, the physics does the rest. Blood takes the low-resistance path, flow through the nidus rises, and the vessels on both sides of it respond to carrying more blood at higher pressure than they were built for. Feeding arteries enlarge and their walls remodel; draining veins arterialise, becoming thick-walled and dilated.
Two consequences follow from that remodelling, and they explain the complications. First, the abnormal vessels are structurally weaker, and a vessel carrying arterial pressure on the venous side is the one most likely to give way. Second, the shunt diverts flow: the brain around the nidus is perfused less well than it should be, which is the mechanism behind a progressive neurological decline in a patient who has never bled.
It also explains the associated aneurysms. Vessels carrying increased flow for years are exposed to it, and aneurysms can form on the feeding arteries or within the nidus. They are a consequence of the shunt rather than a separate condition, and they are looked for on the angiography that maps the malformation.
Whether one can appear later in life
This is a genuinely contested question, and patients deserve a honest answer rather than a reassuring one. The standard position is that a brain AVM is a developmental lesion present from birth. However, there are published reports of malformations appearing on imaging in patients whose earlier studies had been normal, and there are reported cases of a malformation recurring years after one had been documented as obliterated.
How those reports should be read is not settled. A lesion can be present from birth and simply too small to be seen on an earlier study; the appearance of a dural arteriovenous fistula, which is a different and acquired condition, is sometimes conflated with a true AVM; and recurrences after treatment in childhood are the best-documented of the three, which is why long-term follow-up imaging is advised after treatment in a child.
The practical implication is narrow but real: a patient treated as a child is followed with imaging into adult life rather than discharged at the point the first angiogram was clear. For an adult with a sporadic lesion, the position remains that it has been there since development.
The one family pattern that changes the advice
Hereditary haemorrhagic telangiectasia — HHT, also called Osler–Weber–Rendu disease — is an autosomal dominant condition in which the vessels throughout the body form abnormally. People with it have recurrent nosebleeds, small red telangiectases on the lips, tongue and fingertips, and arteriovenous malformations in the lungs, the liver, the gastrointestinal tract and, in a proportion of cases, the brain.
What distinguishes it from the sporadic pattern is multiplicity and family history. Multiple brain malformations in one person, or a brain AVM in someone with a first-degree relative who has one, is a reason to consider the diagnosis. It is not a reason to assume it: most people with a brain AVM and a relative with one do not have HHT, and the assessment is clinical and genetic rather than inferential.
When it is present, the advice changes in three ways that matter. Screening of relatives is offered. Screening for malformations elsewhere — particularly in the lungs, where a shunt carries different and specific risks — is undertaken. And the management of a brain lesion is discussed in the context of a condition with other manifestations, which can alter both the timing and the technique.
What does not cause one, and what does not make it bleed
Several beliefs come up reliably, and none of them is supported. Head injury does not cause an AVM to form; it may cause one to be found, because the scan taken after an injury is often the first imaging a patient has had. Strenuous exercise does not cause one to form, and there is no established basis for prohibiting ordinary exertion on account of an unruptured malformation.
Similarly, none of the following has been established as a trigger for bleeding: a missed dose of medication, a stressful week, flying, or sexual activity. Patients are often told to avoid a long list of ordinary activities, and the list rests on plausibility rather than on evidence. What is reasonable is controlling blood pressure, because that is the one modifiable variable with a clear relationship to vascular risk generally.
Two areas are genuinely uncertain rather than settled. Pregnancy is discussed individually rather than prohibited: the haemodynamic changes of pregnancy are real, and the decision is made on the lesion and the patient rather than on a rule. Anticoagulation is a real consideration, and a patient with a known AVM who needs an anticoagulant has a decision to make with their specialist rather than an automatic contraindication.
What to do with this information
The useful output of a causes page is short. Most patients can be told that the malformation is developmental, that nothing they did caused it, and that it is not passed on. That is the end of the matter for the great majority, and it is worth saying plainly rather than leaving a family to search for a cause.
The minority for whom it is not the end are those with a recognisable pattern: more than one malformation, a first-degree relative with one, recurrent nosebleeds, or telangiectases. For those patients the question to ask a specialist is whether HHT should be considered and whether relatives should be screened — and that is a question answerable in a consultation rather than by worry.
For everyone else, the actionable part of the causes page is the page on living with one. What is modifiable is blood pressure, seizure control, and the plan for follow-up imaging; what is not modifiable is the fact of the diagnosis, and the effort is better spent on the first list than on the second.